Next Article in Journal
Increased Immunogenicity of a Minimally Immunogenic Tumor after Cancer-Targeting Near Infrared Photoimmunotherapy
Previous Article in Journal
Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology: A Randomized Controlled Trial Comparing Push Injections with One-Hour Infusions (The VINCA Trial)
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Article

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study

1
Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna–General Hospital, 1090 Vienna, Austria
2
Diagnostic and Research Institute of Pathology, Comprehensive Cancer Center, Subunit Sarcoma, Medical University of Graz, 8036 Graz, Austria
3
Medical School & Medical Oncology Department, Université de Lille & Centre Oscar Lambret, 59000 Lille, France
4
Direction of Research and Innovation, Centre Oscar Lambret, 59000 Lille, France
5
Department of Cancer Medicine, Gustave Roussy Cancer Campus, 94800 Villejuif, France
6
Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, 69000 Lyon, France
7
Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, 47057 Duisburg, Germany
8
Paris-Saclay University, Paris-Sud University, UVSQ, CESP, INSERM, 94800 Villejuif, France
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Sarcoma Platform Austria.
Cancers 2020, 12(12), 3746; https://doi.org/10.3390/cancers12123746
Received: 16 October 2020 / Revised: 4 December 2020 / Accepted: 9 December 2020 / Published: 12 December 2020
In a double-blind, placebo-controlled, randomized phase 2 trial, Regorafenib provided a clinical benefit to patients with advanced and anthracycline-pretreated soft tissue sarcoma. However, extensive mutational analysis of tumor genes could not identify predictive markers of regorafenib efficacy, including among genes involving in angiogenesis (FLT1, FLT2, FLT3, FLT4, KDR, TEK (TIE2), and VHL). The identification of the precise mechanism of action of multikinase inhibitor in sarcoma and the identification of responding patients requires further clinical studies.
Regorafenib significantly prolonged progression-free survival (PFS) in pretreated patients with advanced non-adipocytic sarcoma (HR = 0.46; p < 0.001) in a placebo-controlled, randomized, phase-II trial (NCT01900743). Thus, here, we assessed the prevalence of 57 biomarkers and their prognostic and predictive values for PFS and overall survival (OS). We analyzed 134/182 patients included in this trial, treated with regorafenib (n = 71, 53%) or placebo (n = 63, 47%). Mutational analyses were performed via full coding sequence analysis for 10 genes, and mutation hotspot panel for 50 genes (four genes in common). H19 was studied with RNA in-situ hybridization. The prognostic and predictive biomarkers’ values were studied only for biomarkers found positive/mutated in at least 10 patients. Overall, 25 out of 57 studied biomarkers, including five out of seven genes involved in angiogenesis, were found mutated/positive in at least one patient, of which 23 biomarkers had low prevalence (fewer than eight out of 134 patients), contrasting with H19 (n = 24, 18%), and TP53 (n = 35, 26%). However, in multivariable models of PFS and OS, including treatment effects and interactions, no significant prognostic or predictive values of the tested biomarkers were observed. Though several promising biomarkers were found to be positive/mutated, none of them were identified as viable predictive and prognostic biomarkers. View Full-Text
Keywords: regorafenib; biomarkers; sarcoma; soft tissue sarcoma; prognosis; multikinase inhibitor regorafenib; biomarkers; sarcoma; soft tissue sarcoma; prognosis; multikinase inhibitor
Show Figures

Figure 1

MDPI and ACS Style

Brodowicz, T.; Liegl-Atzwanger, B.; Penel, N.; Mir, O.; Blay, J.-Y.; Kashofer, K.; Le Cesne, A.; Decoupigny, E.; Wallet, J.; Hamacher, R.; Le Deley, M.-C. Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. Cancers 2020, 12, 3746. https://doi.org/10.3390/cancers12123746

AMA Style

Brodowicz T, Liegl-Atzwanger B, Penel N, Mir O, Blay J-Y, Kashofer K, Le Cesne A, Decoupigny E, Wallet J, Hamacher R, Le Deley M-C. Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. Cancers. 2020; 12(12):3746. https://doi.org/10.3390/cancers12123746

Chicago/Turabian Style

Brodowicz, Thomas, Bernadette Liegl-Atzwanger, Nicolas Penel, Olivier Mir, Jean-Yves Blay, Karl Kashofer, Axel Le Cesne, Emilie Decoupigny, Jennifer Wallet, Rainer Hamacher, and Marie-Cecile Le Deley. 2020. "Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study" Cancers 12, no. 12: 3746. https://doi.org/10.3390/cancers12123746

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop